medRxiv preprint doi: https://doi.org/10.1101/2020.02.25.20026096; this version posted February 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

A method to estimate the incidence of transfusion reaction for the transfusion-treating disease in Chinese hospital

Feng Lin [1], Xue Tian [2], Yonghua Yin[3], Zhong Liu[4]

Institute of blood transfusion, Key laboratory of transfusion adverse reactions,

Chinese academy of medical science and Peking union medical college

No.26 Huacai Road, Chengdu, 610052, People's Republic of China

Summary

Aims: To propose a method to help the clinical doctors to estimate the patients' probability of suffering transfusion reaction during or after the transfusion treatment.

Background: Blood components could be regarded as drugs that may cause adverse reactions while the transfusion is a kind of therapeutic procedure. The incidence of adverse transfusion reaction (ATR) is about 2‰, so some ATR might be neglected by clinical doctors. The ATR may affects patients' prognosis and even causes life threatening problems if not treated quickly and effectively. So, it is necessary to assess the patients' risk of ATR before transfusion and it is very important for ATRs' prevention and management.

Methods/materials: The 79 hospitals reported ATR covered most of the mainland in China except Xizang province. From May 2018 to June 2019, there were about 1500 ATR cases. By Apriori algorithm and complex network method, information of these cases were extracted. The diseases which most probable encounter transfusion reactions after transfusion were screened out and it would be possible to estimate the probability of transfusion reaction of the disease that needs transfusion treatment.

Results: Even though the average incidence of ATR is about 2‰, i.e. on the order of 10^{-3}, for cancer patients the incidence of transfusion reaction is at least on the order of 10^{-2}. And diseases of blood and hematopoietic organs, partus and puerperium, the incidence of transfusion reaction might be higher than the order of 10^{-3}. The gastrointestinal hemorrhage patients need repeated transfusion, however their incidence of ATR might be around the order of 10^{-3}. This means that even though we have thought the history of transfusion might increase the incidence of ATR, it does not increase the incidence significantly.

Conclusion: The incidence of ATR in different groups of patients are different. For instance, in the 0-19 age group, cancer patients transfused by platelet the incidence is higher than 1% much higher than

[1]E-mail: linfeng@ibt.pumc.edu.cn

[2]E-mail: tianxuexzh@student.pumc.edu.cn, Equal contribution with the first author

[3]E-mail: yhyin.ibt@gmail.com

[4]E-mail: liuz@ibt.pumc.edu.cn, Corresponding author

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2020.02.25.20026096; this version posted February 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

the average incidence. The ATR incidence among the gastrointestinal hemorrhage patients transfused by plasma is higher than 0.9‰. And most of the patients in this group also have the history of transfusion. So the transfusion history might increase the ATR incidence, however, it depends on the patients' condition, including the disease they are suffering. Evaluating the patients' condition before transfusion is important. In this study we have proposed a method to valuate the patients' condition before transfusion. Clinical doctors might use the method to estimate the detailed incidence of ATR in their hospital. This might be helpful to prevent the ATR to some extent.

Key words: Transfusion reaction; Apriori algorithm; Complex network; Incidence of adverse transfusion reaction

1 Introduction

Transfusion is a kind of therapeutic procedure performed in hospitalized patients [Panch et al., 2019]. The blood components could be regarded as drugs absorbed by patients through transfusion. Most of the transfusion treatments are homologous blood transfusion, that is why the immune-mediated or infection-mediated adverse reaction might occur. The incidence of ATR is about 2‰ [Uhlmann et al., 2001, Hendrickson et al., 2016]. For clinical doctors, attentions are paid to the disease of the patients. ATR as an adverse reaction from the therapeutic procedure is more likely to skip screening for the symptoms of discomfort. And the mechanism of transfusion is quite complex, which makes it more difficult for doctors to judge whether the symptoms of discomfort is caused by transfusion reaction. For instance, IgE-mediated allergic transfusion reactions is a kind of mechanism, but for the cause for selective protein deficiencies (such as IgA) the mechanism still remains unknown [Garraud, 2019, Savage, 2019]. As a result, if a patient shows discomfort after transfusion, whether the discomfort is caused by transfusion or the disease of the patient itself is judged by experience. As it has already been mentioned that clinical doctors might pay more attention to the disease rather than ATR, some discomfort after transfusion caused by transfusion reaction might be misjudged.

Key laboratory of transfusion adverse reactions have been collecting the clinical cases of transfusion reaction of 79 hospitals in China. Apart from Xizang province, these hospitals cover most of hospitals in the main land of China. There are about 1500 cases collected from May 2018 to June 2019. Our aim is to estimate the incidence of ATR when a specific kind of disease and the transfusion component is determined. Or at least the upper or lower bound of the incidence.

The blood component directly results in the ATR, and the disease often inclined to the needs of certain blood component. So divide the patients into 3 age groups: 0-19, 20-45, and over 45. And each adults groups (over 19) are divided into 2 subgroups: male and female. As the disease are of typical character in different groups. For instance, the female group of age 20-45, a class of the ATR are related to partus and puerperium. In the age group of 0-19, most of the ATR are related to platelet transfusion for the reason of cancer. To qualitatively demonstrate the correlation, complex network method and Apriori

medRxiv preprint doi: https://doi.org/10.1101/2020.02.25.20026096; this version posted February 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

algorithm are taken in use. Both complex network and Apriori algorithm are efficient approach to extract the condition and result from large number of phenomena [Watts and Strogatz, 1998, Boccaletti et al., 2006]. By Apriori algorithm, the causality chains of the blood component and the ATR are screened out. The causality chains of blood component and the disease, ATR forms a complex network. The classification of disease, the blood component, and ATR etc are the nodes in the network. Referring to the mechanism of transfusion reaction [Brand, 2016], it might help the clinical doctors to early identify, correctly dispose and effectively prevent the transfusion reaction. In our study, we find that the cancer patients under the age of 19, the platelet transfusion results in high incidence of transfusion reaction, about 10 times of the average incidence.

The concept, such as Apriori algorithm, causality chains etc would be described in detail in next sections or in the supplementary materials.

2 Materials and Methods

After ethical approval, it would move on to the method introduction. The method mainly contains 2 parts. The first part is to extract information from the patients group with transfusion reaction. The aim of this part is to find out the disease and blood component that most frequently appear. The methods contains Apriori algorithm and complex network. The second part is to estimate the total number of transfusion patients belonging to a specific kind of disease. The aim of this part is to estimate the benchmark of the transfusion patients belonging to a certain specific kind of disease. Combining the work of the 2 parts, the incidence of ATR of a certain component dating back to a certain kind of disease is able to be estimated.

2.1 Ethical approval

All patients involve in the study had given written informed consent by participating hospitals. The current project was approved by the review board of the Research Ethics Committee of Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College on September 18, 2016 (registration number 2016017).

2.2 Information extraction from the transfusion reaction group

Complex network is an efficient method to analyze the relation between the cause and result. When the causes and result are known, they can be abstracted into nodes in the network. Though the result is simple: transfusion reaction, the causes are complex: the blood components, the immunity history of the patients, the disease that results in transfusion are all causes of transfusion reaction. But the causes could be arranged in time ordering: first a patient catches some disease which needs transfusion treatment, second the proper blood component is determined, third the transfusion reaction occurs. Another time ordering is: first a patient catches some disease needs transfusion treatment, second this patient has immunity history, i.e. transfusion, pregnancy etc, third this results in transfusion reaction.

medRxiv preprint doi: https://doi.org/10.1101/2020.02.25.20026096; this version posted February 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Most of the ATRs are related to immune reaction [Delaney et al., 2016]. The direct cause of ATR is blood component. The patients' condition results in the transfusion component. The patients' condition contains: the disease of the patients, the reason of transfusion, the immune history of the patients. Schematic graph of the classification is shown in figure 2.2.



Figure 1: Schematic graph of the causes that result in ATR

The nodes connected by red arrows in figure 2.2 form the "main" clue of ATR. The patients' condition contains complex indirect causes of ATR. However, the clinical doctors directly face these indirect causes of ATR.

Each rectangle in figure 2.2 consists of many subitems. For instance, the rectangle labeled by "disease" consists of the ICD code ranging from A to Z. The rectangle labeled by "blood component" consists of 3 elements named: platelet, erythrocyte, and plasma. For instance, a cancer patient is diagnosed to have internal hemorrhage, and received transfusion treatment by platelet, the transfusion reaction is allergy. We get a causality chain like this:

ICD code belongs to C00-C99→hemorrhage→platelet→allergy

If this patient used to receive the treatment of transfusion, then we can write down another causality chain:

ICD code belongs to C00-C99→history of transfusion→allergy

In our database over 92% of the ATR cases belong to allergy or febrile non-hemolytic transfusion reaction (FNHTR). Other ATR such as transfusion related acute lung injury (TRALI), post-transfusion purpura etc we do not take them into consideration in this study, as the database of these reactions is not large enough for us to use network to analyze so far. The classification of disease is labeled by ICD code. For example, both leukemia and lung cancer are labeled as C00-C99. The frequently occurred causality chains are screened out by Apriori algorithm, as some disease that related to transfusion reaction seldom occur in the database. According to the database, the relevance between transfusion reaction and this kind of disease has no generality.

Each case forms a causality chain. Collecting the causality chains with the same "source", i.e. the same label of disease, and the same "tail", i.e. the transfusion reaction, a network of transfusion reaction forms. In this network, the source and tail are fixed, and the approaches from source to tail are different. The reason why there are different approaches is that each node in figure 2.2 contains many sub-nodes. For instance, there are more than one blood component in the node called "blood component" so on and so forth. The most frequently occurred approach implies that it is the most probable approach from this

medRxiv preprint doi: https://doi.org/10.1101/2020.02.25.20026096; this version posted February 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

disease to transfusion reaction.

In view of complex network, the larger the connection degree of the (sub)-node, the higher the occurrence of the (sub)-node, and the higher the probability to result in transfusion reaction. So define a distance d from node to node. It is in fact the transition probability from one (sub)-node to the other on the causality chain. The shorter the distance the larger the probability i.e. $d^{-1} \propto p$ (p is the probability or frequency of occurrence of the transfusion reaction in a specific kind of disease). d is proportional to the reciprocal of connection degree k:

$$d \propto k^{-a} \tag{1}$$

a is a positive number to be determined. If the total number of the transfusion patient with specific kind of disease is known, comparing all the transition probability of the same kind of disease to the same kind of transfusion reaction, a might be estimated. However in this study, the hospitals did not provide total number of the transfusion patients with specific kind of disease. Only the total number of transfusion patient is provided. So for convenience, set $a = 1$, without missing the qualitative character of d. To describe constructing the distance in detail, we give an example below:

ICD code belongs to C00-C99→hemorrhage→platelet→allergy

The 1st sub-node is "C00-C99". The 2nd node is "hemorrhage" and the 3rd sub-node is "platelet". The 1st transition step is from C00-C99 to hemorrhage. The 2nd transition step is from hemorrhage to platelet and the 3rd transition step is from platelet to allergy. If the connection degree of C00-C99 is k_1, k_2 for the connection degree of hemorrhage, k_3 for the connection degree of platelet, then the distance d is proportional to

$$d \propto k_1^{-1} + k_2^{-1} + k_3^{-1} \tag{2}$$

Even though k_2 and k_3 both connect the first node and the last node, but it does not change the tendency of total distance d.

The patients are divided into 3 age groups: 0-19, 20-45 and over 45. Exempting the 0-19 age group, each group is divided into 2 sub groups: male and female. The reason why the patients are divided by age group is that among the transfusion reaction patients, the 0-19 age group patients mainly suffer cancer; the 20-45 age group male patients mainly suffer the disease of alimentary canal, and female patients mainly suffer puerperium complication or cancer; the over 45 age group patients mainly suffer the disease of alimentary canal and cancer. But patients over the age of 45, most of the female patients have already experienced puerperium. This means that these patients might have immunization history.

Apriori algorithm turn the cases out to be causality chains. According to the connection degree we could figure out the distance to the transfusion reaction. The results would be shown in section3. The algorithm in detail and the code are to be shown in appendix.

medRxiv preprint doi: https://doi.org/10.1101/2020.02.25.20026096; this version posted February 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

2.3 Estimating the incidence of ATR under a specific condition

The hospitals did not provide the total number of transfusion patients with specific disease, for privacy reasons. The hospitals only provided the total number of the transfusion patients. Among the 79 hospitals, only 41 hospitals reported the total number of patients who received transfusion treatment during 2018.05-2019.06.

The information is shown in table 1. The "BC-PC" in table 1 means concentrated platelets. The second row, the total quantity of blood and number of person is reported by the hospital. In table 1 it could be figured out that the average transfusion time of each patient is 1.74. So the average dosage of blood components per time could be estimated. As the average transfusion time for each patients is 1.74, the number of patients that received transfusion treatment is able to be estimated.

Among the 41 hospitals, there are 839 patients showed transfusion reaction belonging to allergy or FNHTR. Apart from these 2 transfusion reaction, there are 51 patients. The total number of transfusion reaction patients is 1255 in the data base of the transfusion reaction patients. Among the 1255 patients, there are 1186 patients showed allergy or FNHTR, and 69 patients showed the transfusion reaction excluding allergy or FNHTR.

Table 1: The total quantity of transfusion patient and blood components

	number	person time	erythrocyte	plasma	BC-PC	Apheresis platelets	cryoprecipitation
total	681077	1188380	1264293.85	136100947.38	10315.5	240190.1	1545916.2

So far it is not possible to discriminant the number of transfusion patients with specific kind of disease only according to the information from the hospitals. To estimate the incidence of transfusion reaction of some specific kind of disease, the "Chinese clinical blood use Research Report (2016)" is needed. This report is completed in 2017, with 1 year postpone. The proportion of blood use in the departments is shown in table 2. The proportion of blood use in department each year is relatively stable. According to the proportion of blood use in department, the number of transfusion patient in each department in the 41 hospitals is able to be estimated according to table 1-2. Even though each department contains more than one kind of specific disease, the number of transfusion patients in each department is the maximum of a certain kind of disease. So at last the estimated transfusion reaction incidence is the lower bound of incidence.

The quantity of blood use in the 41 hospitals are figured out by table 2. The blood use information in detail please please refer to appendix 7. The dosage of blood component is estimated according to the database. The database provided the patients information including the department. The quantity of blood transfusion are classified in each of the department, so the average dosage in each department is shown in table 3. Here the concentrated platelet and the platelet quantity are added up, as in the database the information of platelet is merged. Later the information of cryoprecipitation would be merged into plasma.

medRxiv preprint doi: https://doi.org/10.1101/2020.02.25.20026096; this version posted February 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Table 2: Proportion of blood use in each department

Department	erythrocyte	plasma	platelet	cryoprecipitation
internal medicine	24%	27%	48%	15%
surgery	39%	42%	17%	23%
gynaecology and obstetrics	6%	3%	4%	3%
paediatrics	3%	3%	6%	34%
ICU	9%	15%	6%	15%
others	19%	10%	19%	8%

Table 3: average dosage estimated in each department

Department	erythrocyte	plasma	platelet	cryoprecipitation
internal medicine	4.63	1411	3.86	5.02
surgery	3.92	707	0.11	1.11
gynaecology and obstetrics	4.17	554	2	9.4
paediatrics	2.54	162	2.86	6.95
ICU	7.19	1475	6.78	220
others	4.46	777	4.5	3.14

According to table 9 (this table is in appendix 7) and 3, it is possible to estimate the number of patients in each departments. Table 4 shows the estimated number of patients in each department.

Table 4: Estimated number of patients in the 41 hospitals according to table 9 and 3

Department	erythrocyte	plasma	platelet	cryoprecipitation
internal medicine	65535	26043	31150	46192
surgery	125784	80852	387145	320324
gynaecology and obstetrics	18191	7370	5010	4933
paediatrics	14932	25203	5255	75627
ICU	15825	13840	2216	1054
others	53860	17516	10576	39386

Adding up the number of transfusion reaction patients in each of the department under the classification of disease, and the transfusion component, the lower bound of transfusion reaction incidence is able to be estimated. The results would be shown in section 3. The detail of the transfusion reaction patients classified in disease and the blood components are shown in appendix 7, table 10-11.

medRxiv preprint doi: https://doi.org/10.1101/2020.02.25.20026096; this version posted February 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

3 Results

In this study, the disease that taken into consideration is the disease of the kind screened by complex network and Apriori algorithm. These kinds of disease are "close" to transfusion reaction, i.e. clinically with high incidence of transfusion. This section contains 2 parts. The first part shows the screened diseases and their distance to transfusion reaction. The method including the code of the algorithm in detail is shown in appendix. The second part shows the estimated incidence of ATR.

3.1 The distance to transfusion reaction

Screening the disease category with high occurrence, and calculating the distance to the transfusion reaction, we get the distance to transfusion reaction in figure5-6. The former is the direct reason to transfusion reaction, the latter is the history of immunity that cause transfusion reaction.

Table 5: The distance to transfusion reaction with different sickness (direct reason)

Age	ICD code	component	distance	reaction
0-19	C00-C99	platelet	11.38	allergy
0-19	D50-D89	platelet	16.21	allergy
20-45 (male)	K00-K93	plasma	17.49	allergy
20-45 (male)	C00-C99	platelet	30.5	allergy
20-45 (male)	D50-D89	erythrocyte	41	FNHTR
20-45(female)	C00-C99	erythrocyte	20.16	FNHTR
20-45(female)	D50-D89	plasma	32.16	allergy
20-45(female)	D50-D89	erythrocyte	32.16	FNHTR
20-45(female)	O00-O99	erythrocyte	31.5	FNHTR
20-45(female)	N00-N99	plasma	41	allergy
20-45(female)	N00-N99	erythrocyte	41	FNHTR
>45 (male)	K00-K93 exclude cancer	erythrocyte	15.9	FNHTR
>45 (male)	K00-K93 include cancer	plasma	12.56	allergy
>45 (male)	C00-C99	platelet	27.96	allergy
>45 (male)	I00-I99	plasma	37.6	allergy
>45 (male)	D50-D89	plasma/platelet	40.6	allergy
>45 (female)	C00-C99	erythrocyte	22.6	FNHTR
>45 (female)	C00-C99	platelet	28.6	allergy
>45 (female)	D50-D89 exclude cancer	erythrocyte	20.1	FNHTR
>45 (female)	D50-D89 include cancer	erythrocyte	18.75	FNHTR
>45 (female)	K00-K93	plasma	17.49	allergy
>45 (female)	K00-K93	erythrocyte	18.16	FNHTR

medRxiv preprint doi: https://doi.org/10.1101/2020.02.25.20026096; this version posted February 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Table 6: The distance to transfusion reaction with different sickness (immune history)

Age	ICD code	external reason	distance	reaction
0-19	C00-C99	transfusion	2.875	allergy
0-19	D50-D89	transfusion	4.583	allergy
20-45 (male)	K00-K93	transfusion	5.82	allergy
20-45 (male)	C00-C99	transfusion	12.5	allergy/FNHTR
20-45 (male)	D50-D89	transfusion	12.5	allergy/FNHTR
20-45(female)	C00-C99	transfusion	3.803	allergy
20-45(female)	D50-D89	pregnancy	4.75	allergy/FNHTR
20-45(female)	O00-O99	pregnancy	5.83	allergy/FNHTR
20-45(female)	N00-N99	pregnancy	5.83	allergy/FNHTR
$>$ 45 (male)	K00-K93 exclude cancer	transfusion	3.5	allergy
$>$ 45 (male)	K00-K93 include cancer	transfusion	3.37	allergy
$>$ 45 (male)	C00-C99	transfusion	10	allergy
$>$ 45 (male)	I00-I99	transfusion/allergy history	12.5	allergy
$>$ 45 (male)	D50-D89	transfusion	12.5	allergy/FNHTR
$>$ 45 (female)	C00-C99	pregnancy	3.08	allergy
$>$ 45 (female)	D50-D89 exclude cancer	transfusion/pregnancy	3.25	allergy
$>$ 45 (female)	D50-D89 include cancer	transfusion/pregnancy	3.08	allergy
$>$ 45 (female)	K00-K93	pregnancy	2.83	allergy

medRxiv preprint doi: https://doi.org/10.1101/2020.02.25.20026096; this version posted February 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

So far we classified the distance to transfusion reaction in the category of disease. Next we should estimate the probability of the transfusion reaction of each category.

3.2 Estimating the incidence of ATR

According to table 4, and the combination of the disease, departments and the age groups (see supplementary materials) we can figure out the lower bound of the incidence, see table 7-8.

Table 7: The estimated lower bound of ATR incidence

ICD: C00-C99	department	erythrocyte	plasma	platelet
	internal medicine	0.000381	0.000277	0.00363
	surgery	0.0000795	0.000034897	7.749×10^{-6}
	gynaecology and obstetrics	0.000054972	0.00008128	0.
	paediatrics	0.00033485	0.00002975	0.0106565
	ICU	0.000063191	0.000134282	0.0009025
	other	0.000204	0.00021	0.001607413
ICD: D50-D89	department	erythrocyte	plasma	platelet
	internal medicine	0.000534066	0.000276874	0.00211878
	surgery	0.0000318005	2.49267×10^{-6}	5.16602×10^{-6}
	gynaecology and obstetrics	0.000109944	0.000081281	0.
	paediatrics	0.000133941	0.0000396707	0.00342531
	ICU	0.000189573	0.	0.000902527
	other	0.0000557	0.	0.000661876
ICD: K00-K93	department	erythrocyte	plasma	platelet
	internal medicine	0.000595102	0.000941372	0.0000963082
	surgery	0.0000397507	0.0000448681	0.
	gynaecology and obstetrics	0.	0.	0.
	paediatrics	0.	0.	0.000190295
	ICU	0.000315956	0.000805694	0.000451264
	other	0.0001114	0.0000702963	0.0000945537

medRxiv preprint doi: https://doi.org/10.1101/2020.02.25.20026096; this version posted February 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Table 8: The estimated lower bound of ATR incidence (continued)

ICD: O00-O99	department	erythrocyte	plasma	platelet
	internal medicine	0.	0.	0.
	surgery	0.	0.	0.
	gynaecology and obstetrics	0.000604695	0.00138178	0.000199601
	paediatrics	0.	0.	0.
	ICU	0.0000631912	0.	0.
	other	0.	0.0000175741	0.
ICD: N00-N99	**department**	**erythrocyte**	**plasma**	**platelet**
	internal medicine	0.000198367	0.0000830622	0.0000963082
	surgery	0.	0.0000124634	0.
	gynaecology and obstetrics	0.000109944	0.000081281	0.000199601
	paediatrics	0.	0.	0.
	ICU	0.	0.000134282	0.
	other	0.000148533	0.0000351481	0.0000945537
ICD: I00-I99	**department**	**erythrocyte**	**plasma**	**platelet**
	internal medicine	0.000183108	0.0000415311	0.
	surgery	0.000135152	0.000014956	5.16602×10^{-6}
	gynaecology and obstetrics	0.0000549722	0.	0.
	paediatrics	0.	0.	0.
	ICU	0.0000631912	0.000268565	0.
	other	0.0000185667	0.0000351481	0.0000945537

medRxiv preprint doi: https://doi.org/10.1101/2020.02.25.20026096; this version posted February 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

4 Conclusion and discussion

According to table 5-6 we could see that in China, the highest incidence of transfusion reaction is the 0-19 age group cancer patients. Male patients in the 20-45 age group meet transfusion reaction mainly because of the disease of alimentary canal. Generally speaking cancer and the disease of alimentary canal are most likely to suffer transfusion reaction. For the history of immunity, the patients who used to received transfusion treatment were more likely to meet transfusion reaction. For female patients, pregnancy might be a kind of inducing factor.

Table 7-8 give a strong hint that in the paediatrics department the incidence of transfusion reaction in the group of cancer patients is very high, especially the transfusion of platelet. The incidence is about 10 times higher than the average incidence. As it could only estimate the lower bound of the incidence, attentions of these departments also need to be paid to: cancer patients in internal medicine department, with platelet transfusion; cancer patients in the department excluding the above 5, with platelet transfusion; patients label by ICD D50-D89 in the internal medicine department, with platelet transfusion; patients label by ICD D50-D89 paediatrics department, with platelet transfusion; patients labeled by ICD O00-O99, in gynaecology and obstetrics departments, with plasma transfusion. So it turns out to be clear that the platelet is a "dangerous" blood component. For the patients who are under the age of 19, and who are cancer patient, the incidence of transfusion reaction is much higher than those adults.

It is believed that the incidence of transfusion reaction among the patients with history of transfusion is high. However in this study, the lower bound incidence of transfusion reaction of this kind of group is not always the case. The patients who have disease of canals, especially the hepatic disease, plasma would be transfused frequently, while the transfusion reaction incidence of this kind of group is not higher than the average incidence. So the history of transfusion, more generally, the history of immunity, would increase the incidence of transfusion, however, it depends on the disease. Cancer seems to be a cause of increasing the incidence, rather than the repeated transfusion according to this study.

Cancer patients needs intensive care for the lower bound of transfusion reaction probability is higher than most of the other kinds of disease. For those patients who are labeled by ICD D50-D89, the transfusion reaction might be caused by the history of transfusion, generally speaking, the history of immunity.

For clinical doctors, it is suggested that special attention should be paid to the cancer patients under the age of 19 who are to have platelet transfused. If during or after transfusion, they appear discomfort symptoms, then transfusion reaction might be suspected.

The method proposed in this study would be helpful for the clinical doctors to estimate the patients' condition before transfusion treatment. We have already mentioned that some data is missing in our research, that is why we could only estimate the lower bound of the incidence. But for the transfusion physician in the hospital, the hospital they are working could provide the missing information in our study. So if the transfusion physician could provide the total number of patients received transfusion in each category of disease, the incidence should be more accurate than that figured out in this study. Anyway we just provide a method to the clinical doctors. Perhaps because of the genetic diversity in China, the

medRxiv preprint doi: https://doi.org/10.1101/2020.02.25.20026096; this version posted February 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

incidence of transfusion reaction in each hospital might have significant difference.

5 Competing Interest Statement

The authors have declared no competing interest.

6 Funding Statement

This study was supported by Fundamental Research Funds for the Central Universities (3332019170), CAMS Innovation Fund for Medical Sciences(2016-I2M-3-024), and Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (2018PT32016).

7 Appendix

The detailed appendix will be given in the supplementary materials. For the algorithm, the complex network method readers could refer to the attachment. Here we only list the results that closely related to the tables.

According to table 1-2, we could first figure out the quantity of blood component use in each department. It could be seen in table 9. A part from ICU and the paediatrics departments, the blood use are almost the same.

Table 9: blood component quantity use in each department

Department	erythrocyte	plasma	platelet	cryoprecipitation
internal medicine	303430.524	36747255.79	120242.688	231887.43
surgery	493074.6015	57162397.9	42585.952	355560.726
gynaecology and obstetrics	75857.631	4083028.421	10020.224	46377.486
paediatrics	37928.8155	4083028.421	15030.336	525611.508
ICU	113786.4465	20415142.11	15030.336	231887.43
others	240215.8315	13610094.74	47596.064	123673.296

The age group distribution of the patients who suffered from transfusion reaction are given in table10-11

medRxiv preprint doi: https://doi.org/10.1101/2020.02.25.20026096; this version posted February 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Table 10: The age group distribution of the patients who have transfusion reaction

Department	0-19	20-45(male)	20-45(female)	> 45(male)	> 45(female)
internal medicine	83	60	45	119	101
surgery	6	14	15	64	45
gynaecology and obstetrics	0	0	40	0	2
paediatrics	90	0	0	0	0
ICU	12	11	4	21	11
other	1	4	22	27	42
total	192	89	126	231	201

Table 11: The age group distribution of the patients who have transfusion reaction

ICD code of disease	0-19	20-45(M)	20-45(F)	> 45(male)	> 45(female)
C00-C99	128	22	29	60	54
D50-D89	68	15	21	21	45
K00-K93	8	34	5	72	46
O00-O99	0	0	31	0	0
N00-N99	2	2	15	10	14
I00-I99	0	8	3	26	13

References

[Boccaletti et al., 2006] Boccaletti, S., Latora, V., Moreno, Y., Chavez, M., and Hwang, D.-U. (2006). Complex networks: Structure and dynamics. *Physics Reports*, 424(4):175 – 308.

[Brand, 2016] Brand, A. (2016). Immunological complications of blood transfusions. *La Presse Médicale*, 45(7, Part 2):e313 – e324.

[Delaney et al., 2016] Delaney, M., Wendel, S., Bercovitz, R. S., Cid, J., Cohn, C., Dunbar, N. M., Apelseth, T. O., Popovsky, M., Stanworth, S. J., Tinmouth, A., Watering, L. V. D., Waters, J. H., Yazer, M., and Ziman, A. (2016). Transfusion reactions: prevention, diagnosis, and treatment. *The Lancet*, 388(10061):2825 – 2836.

[Garraud, 2019] Garraud, O. (2019). How to reposition the benefice-risk balance to safely transfuse patients in non-vital situations? *Transfusion Clinique et Biologique*, 26(3):171 – 173.

[Hendrickson et al., 2016] Hendrickson, J. E., Roubinian, N. H., Chowdhury, D., Brambilla, D., Murphy, E. L., Wu, Y., Ness, P. M., Gehrie, E. A., Snyder, E. L., George Hauser, R., et al. (2016). Incidence of transfusion reactions: a multicenter study utilizing systematic active surveillance and expert adjudication. *Transfusion*, 56(10):2587–2596.

medRxiv preprint doi: https://doi.org/10.1101/2020.02.25.20026096; this version posted February 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

[Panch et al., 2019] Panch, S. R., Montemayor-Garcia, C., and Klein, H. G. (2019). Hemolytic transfusion reactions. *New England Journal of Medicine*, 381(2):150–162.

[Savage, 2019] Savage, W. J. (2019). Allergic transfusion reactions. In *Transfusion Medicine and Hemostasis*, pages 389–392. Elsevier.

[Uhlmann et al., 2001] Uhlmann, E. J., Isgriggs, E., Wallhermfechtel, M., and Goodnough, L. T. (2001). Prestorage universal wbc reduction of rbc units does not affect the incidence of transfusion reactions. *Transfusion*, 41(8):997–1000.

[Watts and Strogatz, 1998] Watts, D. J. and Strogatz, S. H. (1998). Collective dynamics of ' small-world' networks. In *Nature*, pages 440–442.